A retrospective real-world single-arm study evaluating the efficacy and safety of neoadjuvant chemotherapy in patients with selected limited-stage small-cell lung cancer

Neoadjuvant chemotherapy combined with surgery could be a potential treatment strategy for LS-SCLC, with a high proportion of patients achieving an MPR, and manageable safety profile, that did not compromise surgical resection. Further prospective clinical trials are warranted to delineate the benefits of neoadjuvant chemotherapy and optimize LS-SCLC treatment.